Xinting Xia

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer

Juanjuan Feng, Zhongwei Hu, Xinting Xia et al. · Oncogene · 2023 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer

Juanjuan Feng, Zhengke Lian, Xinting Xia et al. · Acta Pharmaceutica Sinica B · 2022 · 62 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance

Peng He, Juanjuan Feng, Xinting Xia et al. · Journal of Medicinal Chemistry · 2023 · 27 citations

Medicine, Oncology, Pharmacology +17

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers

Juanjuan Feng, Xuanzheng Xiao, Xinting Xia et al. · Cancer Cell · 2025 · 23 citations · Full text

Medicine, Oncology, Pharmacology +15

Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-<i>d</i>]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRAS^G12D Inhibitors

Xuanzheng Xiao, Juanjuan Feng, Jing Ma et al. · Journal of Medicinal Chemistry · 2023 · 18 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16